# Pizarra — PT-pseudo_b9aa0df93f2a (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9aa0df93f2a
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 5.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 1.47 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 49.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8111057 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: amlodipine, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 5.5 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 49 mL. csPCa 0.81.

Vitals: weight 116 kg, height 175 cm, BMI 37.9, BP 149/83 mmHg, HR 65 bpm. Smoking: Non-smoker.

Chief complaint: Assessment of a 5.5 ng/mL prostate-specific antigen elevation alongside a prior positive biopsy result.

History: A married, 71-year-old warehouse manager who lives alone with his spouse listed as the primary contact. Initial workup began in late 2023 after an elevated prostate-specific antigen was detected. He experiences moderate lower urinary tract symptoms, scoring 15 on the IPSS, mainly due to nocturia and a diminished urinary stream, while explicitly denying haematuria or pelvic discomfort. His medical background includes well-managed hypertension treated with amlodipine, lisinopril, and metoprolol, plus an arthroscopic knee procedure in his forties. He stays physically active by cycling roughly 30 kilometres three times weekly, drinks about two units of alcohol each week, and reports no tobacco use. A recent audiology visit identified mild age-related presbycusis, currently managed with hearing aids. He has voiced significant apprehension about invasive interventions and insists on detailed explanations of every potential step prior to providing consent.

Physical examination: Normal DRE: The prostate is symmetrically enlarged, smooth, and firm, with no palpable nodules or asymmetries. General inspection is unremarkable. Blood pressure measures 149/83 mmHg with a regular heart rate of 65 beats per minute. Abdominal palpation shows no suprapubic tenderness or distended bladder. Peripheral lymphadenopathy and bone tenderness are absent.

Patient info: warehouse manager; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 2 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.51 +/- 0.19   (95% CI 0.14-0.87)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.9 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=5.5, age=71.0, psad=0.12, dre_ord=0.0, vol=49.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (1.47 ng/mL/yr) against the prior PSA (3.8 ng/mL) and the current PSA (5.5 ng/mL), which suggests a rapid rise. It also could not incorporate the specific findings from the mpMRI report (PI-RADS 5) or the full context of the PSA history/laboratory panel, which are crucial for interpreting the risk stratification beyond the static PI-RADS score.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier decision (0.51 +/- 0.19). This is problematic because the patient has a PI-RADS 5 and a high csPCa probability (0.8111057). The prior fails to account for the high clinical significance indicated by the PI-RADS 5 and the rising PSA velocity, which might push the decision away from 'discuss' towards a stronger recommendation for biopsy. Furthermore, the prior ignores the fact that a prior biopsy was positive, which fundamentally changes the interpretation of the current findings.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report confirms high-grade features or specific lesion characteristics, it would strengthen the case for biopsy.
  <document> PSA history (trend) -> If the trend shows a steeper rise or a more concerning trajectory, it would increase the urgency for intervention.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial diagnosis or any prior discussions about intervention thresholds.
  <document> laboratory results (full panel) -> This panel might provide context on other markers or baseline health that influences risk assessment.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  Subject: mpMRI Prostate | Institution: LUMC, Leiden | Date: 28 January 2025

  Indication: Assessment of escalating prostate-specific antigen (5.5 ng/mL) alongside a prior positive biopsy result.

  FINDINGS:
  The gland measures 49.0 mL in volume and exhibits subtle asymmetry. A discrete, approximately 12 mm focus is noted within the left peripheral zone at the mid-gland level. T2-weighted sequences show marked hypointensity. Diffusion-weighted imaging confirms restricted diffusion with correspondingly reduced apparent diffusion coefficient values. Dynamic contrast-enhanced sequences display early, focal enhancement compared to adjacent tissue. No extraprostatic extension, seminal vesicle invasion, or suspicious lymphadenopathy is present.

  IMPRESSION:
  PI-RADS 5 lesion in the left mid peripheral zone. PSAD 0.12 ng/mL/mL. csPCa predicted probability 0.8111057

  **PSA history**
  {"case_id": "PT-pseudo_b9aa0df93f2a", "psa_trend": [{"date": "Aug 2023", "val": 1.5}, {"date": "May 2024", "val": 1.2}, {"date": "Feb 2025", "val": 5.5}]}

  **previous GP / urology consultation notes**
  {"date": "10 Feb 2024", "author": "Dr. F. de Boer (GP)", "text": "Review of escalating prostate-specific antigen values, which climbed from 2.5 ng/mL in August 2023. Because of the prior positive biopsy and the upward trend, a referral to the urology outpatient clinic was scheduled for further evaluation and imaging."}

  **laboratory results**
  {"name": "PSA", "val": "5.5 ng/mL", "date": "18 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.05 ng/mL", "date": "18 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "19%", "date": "18 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "14.6 g/dL", "date": "18 Jan 2025", "flag": ""}, {"name": "WBC", "val": "5.7 x10^9/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "227 x10^9/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "78 umol/L", "date": "18 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "18 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "9.3 nmol/L", "date": "18 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "41 U/L", "date": "18 Jan 2025", "flag": ""}, {"name": "LDH", "val": "122 U/L", "date": "18 Jan 2025", "flag": ""}, {"name": "HbA1c", "val": "5.8 %", "date": "18 Jan 2025", "flag": ""}

NOT RETRIEVED
  get_family_history: Not called because the rule states not to call this tool for this type of work-up.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the left mid peripheral zone.
  csPCa predicted probability 0.8111057.
  PSA velocity of 1.47 ng/mL/yr, indicating a rapid rise.
  Prior positive biopsy result.

  AGAINST sampling this patient now:
  Prior positive biopsy result.

WHERE THIS LEANS
  The retrieved evidence strongly argues for sampling due to the high-risk MRI finding (PI-RADS 5) and the rapidly rising PSA trend, which aligns with the LLM-1-GAP-ANALYST's concern that the prior was too conservative. This leans towards a strong recommendation for biopsy.

[Sections actually revealed in this consultation: psa_trend, radiology_report, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the presence of a PI-RADS 5 lesion and a rapidly rising PSA velocity of 1.47 ng/mL/yr, which strongly argues for further tissue sampling. This decision is driven by the high-risk imaging finding (PI-RADS 5) and the concerning PSA trend, which overrides the caution suggested by the prior positive biopsy. The evidence converges on the need to re-evaluate the disease status given the high-risk features.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: psa_trend, radiology_report, previous_notes, laboratory_results
